secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001599298-23-000009
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit reports preliminary cash of at least $648M; shareholders authorize share increase and reverse split
--------------------------------------------------------------------------------

- Preliminary unaudited cash, equivalents and escrow balance no less than $648M as of Dec 31, 2022.
- Includes $300M upfront to Akeso held in escrow pending HSR clearance for ivonescimab license.
- Stockholders approved increasing authorized shares from 350M to 1B and a reverse stock split (1:5 to 1:10), board discretion within one year.
- Company to present at 41st J.P. Morgan Healthcare Conference on Jan 9, 2023, highlighting ivonescimab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/smmt-20230106.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer